AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14694935
Drug: Palivizumab prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palivizumab prophylaxis (5 monthly intramuscular injections at 15 mg/kg)
Trial: 8595788
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB) hydrochloride as add-on therapy
Trial: 1107360
Drug: Loxapine succinate
RxNorm normalized name: Loxapine Succinate
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loxapine succinate (40-80 mg daily)
Trial: 1107360
Drug: Trifluoperazine (20-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluoperazine (20-50 mg daily)
Trial: 29138547
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg tiotropium for 4 weeks
Trial: 29138547
Drug: 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg indacaterol for 4 weeks
Trial: 29138547
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of tiotropium and indacaterol for 4 weeks
Trial: 21447368
Drug: Laser irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser irradiation (L)
Trial: 21447368
Drug: Fluoride (AmF/NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride (AmF/NaF gel) application (F)
Trial: 19416526
Drug: LPS (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS (4 ng/kg) administered intravenously
Trial: 19416526
Drug: RWJ-67657 (p38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-67657 (p38 MAP kinase inhibitor) administered 30 minutes before LPS infusion
Trial: 9681666
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg oral or intravenous for healthy subjects; 20 mg oral for patients with renal insufficiency or hepatic cirrhosis)
Trial: 9681666
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg oral for patients with hepatic cirrhosis)
Trial: 1955122
Drug: Cisapride (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.3 mg/kg PO t.i.d.)
Trial: 31734696
Drug: CMV intravenous
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV intravenous immunoglobulin (IVIG)
Trial: 30597112
Drug: lemborexant 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lemborexant 2.5 mg
Trial: 2744064
Drug: zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zopiclone 7.5 mg
Trial: 25378034
Drug: 5% oral
RxNorm normalized name: glucose 45% oral gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% oral glucose solution
Trial: 21305270
Drug: ROSU 10
RxNorm normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ROSU 10 mg/day starting 5 days before the infusion of ZOL for a total period of 11 days
Trial: 21305270
Drug: No ROSU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ROSU treatment
Trial: 21305270
Drug: ROSU 10
RxNorm normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ROSU 10 mg/day
Trial: 19824553
Drug: Oral-B Exceed
RxNorm normalized name: IODINE 5 g in 1 L TOPICAL SOLUTION [Exceed]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Exceed toothbrush
Trial: 30519955
Drug: Control intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control intervention (1.8 ml of 2% lidocaine with 1:100,000 adrenaline)
Trial: 26260081
Drug: Dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of cannabis consumption
Trial: 21957588
Drug: Thymogen preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymogen preparation administered by intranasal instillation of 100 mg once a day for 7 days before surgery
Trial: 21957588
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution (placebo) administered in the same scheme
Trial: 19703279
Drug: Oxytocin 5
RxNorm normalized name: oxytocin 5 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 5 IU bolus and 40 IU infusion
Trial: 19703279
Drug: Oxytocin 5
RxNorm normalized name: oxytocin 5 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 5 IU bolus and placebo infusion
Trial: 17367495
Drug: CHF 4227
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 4227 (5-400 mg single doses)
Trial: 17367495
Drug: CHF 4227
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 4227 (5-100 mg multiple doses)
Trial: 17367495
Drug: CHF 4227
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 4227 (5 and 10 mg)
Trial: 14702440
Drug: Drotrecogin alfa
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alfa (activated) at 24 micro g/kg per hour for 96 hours (part 2)
Trial: 14702440
Drug: Drotrecogin alfa
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alfa (activated) at escalating doses of 6, 12, 24, and 36 micro g/kg per hour for 6 hours (part 1)
Trial: 11736869
Drug: Alosetron 1
RxNorm normalized name: alosetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron 1 mg twice daily for 15 days
Trial: 11736869
Drug: Theophylline 200
RxNorm normalized name: theophylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 200 mg twice daily alone for 8 days
Trial: 7628025
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg.kg‐1
Trial: 9243685
Drug: Diazepam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.25 mg.kg‐1 with droperidol 0.25 mg.kg‐1
Trial: 9243685
Drug: Trimeprazine 2
RxNorm normalized name: trimeprazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimeprazine 2 mg.kg‐1
Trial: 8301808
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition alone (n = 21)
Trial: 3718367
Drug: Oral fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fenoterol
Trial: 23620935
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (smectite powder and live combined bifidobacterium and lactobacillus tablets), orally administered.
Trial: 21623600
Drug: sulodexide 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulodexide 75 mg daily
Trial: 21623600
Drug: sulodexide 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulodexide 150 mg daily
Trial: 14759231
Drug: Amoxicillin/clavulanate 2000/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 2000/125 mg twice daily
Trial: 16446376
Drug: Amoxicillin/clavulanate 875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 875/125 mg three times daily
Trial: 9834042
Drug: 10-minute intravenous
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-minute intravenous infusion of 5 microg x kg(‐1) hCRF
Trial: 9834042
Drug: 180-minute intravenous
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180-minute intravenous infusion of 5 microg x kg(‐1) hCRF
Trial: 9834042
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of hCRF (300, 600, or 1200 microg)
Trial: 9834042
Drug: Repetitive administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repetitive administration of hCRF
Trial: 8077989
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) and fluorouracil (FU)
Trial: 8077989
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) and fluorouracil (FU) with a 6-hour interval
Trial: 49736
Drug: Propranolol (0-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0-1 mg/kg)
Trial: 49736
Drug: Practolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (1 mg/kg)
Trial: 49736
Drug: Acebutolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (1 mg/kg)
Trial: 30136743
Drug: Doll Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doll Therapy (DT)
Trial: 28865924
Drug: 55.8 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 55.8 Gy (RBE) of fractionated combined proton-photon radiation therapy
Trial: 28865924
Drug: 63.0 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 63.0 Gy (RBE) of fractionated combined proton-photon radiation therapy
Trial: 28865924
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (55.8 Gy and 63.0 Gy)
Trial: 21802303
Drug: Concurrent cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cognitive task (silent backward counting)
Trial: 19374676
Drug: Nasal cannulae
RxNorm normalized name: CANNULA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannulae (5 L/minute)
Trial: 19374676
Drug: Oxygen mask
RxNorm normalized name: oxygen masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen mask (5 L/minute)
Trial: 2663407
Drug: Aceclofenac 100
RxNorm normalized name: aceclofenac 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aceclofenac 100 mg
Trial: 10961730
Drug: mesalamine 1
RxNorm normalized name: mesalamine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalamine 1 g two times a day plus Saccharomyces boulardii 1 g daily
Trial: 10961730
Drug: mesalamine 1
RxNorm normalized name: mesalamine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalamine 1 g three times a day
Trial: 1611155
Drug: Glyburide 10
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide 10 mg/d
Trial: 28394002
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of omega-3 acids daily for 12 weeks
Trial: 28394002
Drug: Placebo (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (corn oil 1 g daily for 12 weeks)
Trial: 23046851
Drug: Oral methamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methamphetamine (0, 8 or 16 mg)
Trial: 16740174
Drug: PV measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PV measurement using the constant flow method (PVCF); insufflated volume = 1120 +/- 115 ml, plateau pressure = 46 +/- 11 cmH2O
Trial: 16740174
Drug: PV measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PV measurement using a 2 l super syringe (PVSS); insufflated volume = 1824 +/- 381 ml, plateau pressure = 46 +/- 9 cmH2O
Trial: 15356367
Drug: Antimicrobial wound
RxNorm normalized name: Anasept Antimicrobial Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial wound cleanser (0.057% sodium hypochlorite in isotonic saline solution)
Trial: 10699770
Drug: Inhaled Entonox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Entonox (50% nitrous oxide, 50% oxygen)
Trial: 10699770
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam and meperidine
Trial: 9432334
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole once in the morning, 200 mg clarithromycin twice daily, and 250 mg metronidazole twice daily for 1 week (LCM1)
Trial: 9432334
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole once in the morning, 200 mg clarithromycin twice daily, and 500 mg metronidazole twice daily for 1 week (LCM2)
Trial: 3593624
Drug: Y-8894 50
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y-8894 50 mg
Trial: 3593624
Drug: Nortriptyline 50
RxNorm normalized name: nortriptyline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline 50 mg
Trial: 31918685
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment guided by best-corrected visual acuity (BCVA) loss (Group I)
Trial: 31918685
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment guided by BCVA loss and/or signs of disease activity on optical coherence tomography (OCT; Group II)
Trial: 30025734
Drug: USCDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USCDT with 4 mg tPA/lung for 2 hours
Trial: 30025734
Drug: USCDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USCDT with 4 mg tPA/lung for 4 hours
Trial: 30025734
Drug: USCDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USCDT with 6 mg tPA/lung for 6 hours
Trial: 30025734
Drug: USCDT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USCDT with 12 mg tPA/lung for 6 hours
Trial: 25786048
Drug: Acetyl L-carnitine
RxNorm normalized name: Nature's Way Acetyl L-Carnitine Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl L-carnitine 1500 mg/day (500 mg t.i.d.)
Trial: 18203046
Drug: 5-HT stimulation
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT stimulation during treatment
Trial: 18203046
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment in patients with depression
Trial: 16365055
Drug: Betaine 3
RxNorm normalized name: betaine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 3 g
Trial: 16365055
Drug: Betaine 6
RxNorm normalized name: betaine 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 6 g
Trial: 16365055
Drug: Betaine 1
RxNorm normalized name: betaine 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine 1 g
Trial: 16365055
Drug: Betaine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (all doses)
Trial: 14564940
Drug: Multi‐micronutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi‐micronutrient supplement (S)
Trial: 14564940
Drug: Multi‐micronutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi‐micronutrient supplement plus test meal (MS)
Trial: 6588726
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish treatment every 6 months
Trial: 29926431
Drug: Therapeutic education
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic education programme 'PETAL' for laryngectomised patients and their close relations; details on dosage and duration not specified.
Trial: 29926431
Drug: Pilot phase
RxNorm normalized name: Picot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilot phase of the programme; details on dosage and duration not specified.
Trial: 29926431
Drug: Prospective intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospective intervention 'replication' phase; details on dosage and duration not specified.
Trial: 29926431
Drug: Cluster-randomised multicentric
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster-randomised multicentric comparative intervention phase; details on dosage and duration not specified.
Trial: 29144178
Drug: Evening-dosing of
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Evening-dosing of DCF regimen
Trial: 29144178
Drug: Morning-dosing of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning-dosing of DCF regimen
Trial: 26853293
Drug: Subepidermal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subepidermal triamcinolone injections (4mg per cc, 5mm intervals until complete blanching)
Trial: 20207720
Drug: 100% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% of the RDA for SAA, 15 mg/kg APAP given on day 3
Trial: 20207720
Drug: 0% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% of the RDA for SAA, 15 mg/kg APAP given on day 3
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl 40 mg single dose
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl 60 mg single dose
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl 10 mg repeated doses for 14 days
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl 20 mg repeated doses for 14 days
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl repeated doses
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl single dose
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl 20 mg single dose
Trial: 9590466
Drug: KA 672-HCl
RxNorm normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KA 672-HCl 20 mg repeated doses
Trial: 3384164
Drug: Amoxycillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanic acid (2.2 g preoperative dose)
Trial: 3384164
Drug: Cefuroxim (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxim (1.5 g) combined with Metronidazole (0.5 g)
Trial: 31010007
Drug: CIPA nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIPA nutrition screening and treatment
Trial: 24120754
Drug: Progressive Resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive Resistance Training (PRT) programme, trained twice a week for 10 weeks at a community gymnasium with a physiotherapy student mentor using pin-loaded weight machines
Trial: 27287343
Drug: Active PEMF
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PEMF treatment
Trial: 21493648
Drug: S/GSK1349572 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/GSK1349572 50 mg with multivitamin (MVI; One A Day Maximum)
Trial: 21493648
Drug: S/GSK1349572 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/GSK1349572 50 mg with liquid antacid (Maalox Advanced Maximum Strength)
Trial: 21493648
Drug: S/GSK1349572 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/GSK1349572 50 mg 2 h before an antacid
Trial: 17110827
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fatty acids (3 g daily)
Trial: 11696730
Drug: Intrarectal 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal 2% lidocaine gel
Trial: 2162027
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus vaccine serotype 3 (RRV) 10(5) pfu
Trial: 2162027
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus vaccine serotype 3 (RRV) 10(4) pfu
Trial: 2162027
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus vaccine serotype 3 (RRV) 10(3) pfu
Trial: 31126566
Drug: Lentil savigh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentil savigh (roasted lentil flour) 30 grams daily (three 10-gram sachets in the morning)
Trial: 31126566
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 500 mg every eight hours
Trial: 22330824
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg V0191 once daily for 24 weeks
Trial: 22330824
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily for 24 weeks